A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study. The study consists of 3 periods: * Screening period: 2 to 4 weeks. * Treatment period: 24 weeks. * Post-intervention follow-up period: 16 weeks. The study duration will be approximately 42 to 44 weeks for each participant (including screening, treatment, and follow-up periods). The total number of planned study visits for each participant will be 6.

NCT Number	NCT06293053
Lead Sponsor	Sanofi Collaborators: Regeneron Pharmaceuticals
Conditions	Prurigo Nodularis
Enrollment	18 participants
Start Date	2024-05-15
Primary Completion	2027-10-28 (estimated)
Study Completion	2027-11-03 (estimated)
Updated on ClinicalTrials.gov	2026-01-15